Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
George Washington University · University of Lübeck · +9 more institutions
Abstract
Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13, prevents the formation of the interleukin-4Rα-interleukin-13Rα1 heterodimer receptor signaling complex.
We conducted two identically designed, 52-week, randomized, double-blind, placebo-controlled, phase 3 trials; both trials included a 16-week induction period and a 36-week maintenance period. Eligible patients with moderate-to-severe atopic dermatitis (adults [≥18 years of age] and adolescents [12 to
Citation impact
- FWCI
- 79.99
- Percentile
- 100%
- References
- 50
Authors
12- JIJonathan I. SilverbergCorresponding
George Washington University, University of Lübeck
- EGEmma Guttman‐Yassky
University of Lübeck, Icahn School of Medicine at Mount Sinai
- DTDiamant Thaçi
University of Lübeck
- ADAlan D. Irvine
Trinity College Dublin, University of Lübeck
- LSLinda Stein Gold
Henry Ford Health System, University of Lübeck
Topics & keywords
- Atopic dermatitis
- Dermatology
- Medicine
- Good health and well-being